Back to search

University of British Columbia

Basal ganglia structure and the effects of neuroleptic treatment in schizophrenia

Abstract

dc:description

Schizophrenia is a complex mental illness of unknown etiology. Clinical research has suggested that abnormalities of the basal ganglia are present in schizophrenia. Whether these abnormalities are present at the beginning of illness or progress with time remains controversial. Concomitantly, antipsychotic treatments, particularly traditional neuroleptics, may exert metabolic effects on the basal ganglia, but the effects of new atypical antipsychotic are unknown. To elucidate the nature of underlying basal ganglia structure and the effects of antipsychotic treatment on striatal morphology, clinical signs and symptoms, three MRI studies of basal ganglia volumes were conducted. In study A, baseline volumes in a cohort of drug-naive first episode psychosis (FEP) patients, chronically treated schizophrenia patients and healthy controls were assessed. Chronically treated patients had larger basal ganglia volumes compared to both never-medicated patients and healthy controls. Never-medicated patients' basal ganglia volumes were not different from controls. In study B, extrapyramidal symptoms (EPS) and their relationship to neuroleptics and striatal volumes were examined. Prior to neuroleptic treatment, 39% of FEP patients had EPS at baseline. FEP patients who presented with parkinsonism had larger left caudate volumes than those who did not. In study C, the effects on basal ganglia volumes and EPS after switching patients from risperidone or typical antipsychotics to olanzapine were examined. Patients previously treated with typicals had decreases in putamen and globus pallidus volume after switching. Patients previously on risperidone had a decrease in caudate volume after switching. Patients maintained on risperidone had no changes in basal ganglia volumes. Severity and prevalence of EPS were unchanged after switching. No underlying volumetric abnormalities of the basal ganglia in drug-naive first-episode schizophrenia were observed in the cohort of patients included in this thesis. However, movement disorders were seen in a notable portion of drug-naive schizophrenia patients, suggesting that abnormalities of the basal ganglia or circuits of the basal ganglia are present and may be subtle. Atypical neuroleptics do not induce additional EPS at clinically effective doses. Chonic exposure to atypical neuroleptics is not associated with striatal hypertrophy, and in the case of olanzapine, may reduce caudate volumes in some patients.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Neuroscience
Grantor dc:publisher
University of British Columbia
Year dc:date
2002

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lang, Donna Jane-Mai

Rights

dc:rights
Statement dc:rights
  • For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/13532

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Lang, Donna Jane-Mai. Basal ganglia structure and the effects of neuroleptic treatment in schizophrenia. doctoral thesis, University of British Columbia, 2002. http://hdl.handle.net/2429/13532